THC Liver Enzyme Interactions
THC inhibits multiple cytochrome P450 enzymes, specifically CYP3A4, CYP2C9, CYP2C19, CYP1A2, CYP2B6, and CYP2C8, as well as UGT enzymes (UGT1A9 and UGT2B7). 1
Primary Metabolic Pathways
THC metabolism occurs through two main enzyme families:
Cytochrome P450 Enzymes (Phase I)
- CYP2C9: The dominant enzyme for THC metabolism, responsible for approximately 82% of THC depletion and 99% of 11-OH-THC formation 2
- CYP3A4/3A5: Major contributors to alternative hydroxylation pathways in the cyclohexenyl ring 3
- CYP2C19: Secondary pathway for 11-OH-THC formation 3
- CYP2D6, CYP1A2, CYP2B6, CYP2C8: Minor contributors to THC metabolism 1, 2
UGT Enzymes (Phase II)
- UGT2B7 and UGT1A9: Responsible for approximately 60% of 11-OH-THC depletion through glucuronidation 2
Clinical Significance of Drug Interactions
The 2024 ASCO guideline identifies three risk categories for THC drug interactions:
Very High Risk
- Warfarin: Documented bleeding complications 1
High Risk
- Buprenorphine
- Tacrolimus 1
Moderate Risk
- Chemotherapeutic agents: Potential for increased toxicity or decreased efficacy due to shared CYP450 metabolism 1
Important Caveats
The actual clinical risk of most THC drug interactions remains low despite the biochemical inhibition potential. 1 This is because:
- In vitro inhibition does not always translate to clinically significant interactions
- Limited clinical data exists on real-world THC drug interactions
- Most documented interactions involve narrow therapeutic index medications
However, clinicians cannot provide scientifically supported answers for most potential THC-drug interactions due to the paucity of clinical pharmacokinetic data. 1 The variability in cannabis preparations (strain, concentration, formulation) makes it impossible to extrapolate findings from one product to another. 1
Practical Monitoring Approach
When patients use THC alongside medications metabolized by CYP2C9, CYP3A4, or CYP2C19:
- Monitor for altered drug levels in medications with narrow therapeutic indices
- Watch for unexpected efficacy changes in chemotherapy or immunosuppressants
- Check INR more frequently in warfarin users
- Consider dose adjustments based on clinical response rather than predicted interactions
The metabolite 11-OH-THC (the active psychoactive metabolite) also inhibits CYP2B6, CYP2C9, and CYP2D6, extending the interaction potential beyond the parent compound. 4